Health Condition 1: L639- Alopecia areata, unspecified
Conditions
Interventions
Intervention1: Intralesional Triamcinolone Acetonide injection 5 mg/ml: Intra-lesional injection of triamcinolone acetonide in patch of alopecia areata (10mg/ml)
under aseptic conditions, using a 0.5 inch long, 30 gauge needle, fitted to an insulin syringe, a session every 3 weeks for 4 sessions or until complete hair re-growth whichever is earlier. The ste
under aseptic conditions, using a 0.5 inch long, 30 gauge needle, fitted to an insulin syringe, a session every 3 weeks for 4 sessions or until complete hair re-growth whichever is earlier. 0.1 ml
Sponsors
NIL
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of both sexes(males and females), aged >13 years with AA, 2. Patients having AA on the scalp with 3. Patients who had not taken any form of treatment in the last 8 weeks. 4. Patients who are willing to sign the written consent form before participating in the study
Exclusion criteria
Exclusion criteria: 1. Patients aged 2. Patients with alopecia totalis, alopecia universalis and ophiasis. 3. Patients having skin diseases affecting the scalp. 4. Patients with active infection at the local site and with keloidal tendency. 5. Pregnant or lactating women or immuno-compromised patients or patients with bleeding or coagulation disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in Severity Alopecia Tool (SALT) Score, 5 point semi-quantitative Re Growth Scale (RGS) and Dermoscopic AssessmentTimepoint: At Baseline,3 weeks, 6 weeks, 9 weeks,12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Assess side effects with two concentrations of intra-lesional injection of triamcinolone acetonideTimepoint: Every 3 weeks then at the 3 months of therapy from baseline (3weeks after the 4th session) | — |
Countries
India
Contacts
Public ContactDr Bhavnish Bansal
All India Institute of Medical Sciences, Bathinda
Outcome results
None listed